Transcenta Therapeutics, a global clinical stage biopharmaceutical company, entered into a strategic collaboration and non-exclusive licensing agreement with EirGenix, a CDMO based in Taiwan. Transcenta granted EirGenix a non-exclusive license to use its highly intensified continuous bioprocessing (HiCB) platform, including continuous perfusion and integrated hybrid continuous purification process technologies, along with process documentation, expertise, and regulatory support packages. Transcenta will be eligible to receive substantial upfront and milestone payments, as well as future royalty payments associated with the commercial use of the licensed technologies, reflecting the long-term value both companies expect to create through this collaboration, according to Transcenta officials. EirGenix will adopt Transcenta’s HiCB platform to support its biologics development programs and manufacturing operations. EirGenix plans to apply the HiCB platform to serve CDMO clients pursuing intensified and continuous manufacturing solutions. “By enabling others to implement HiCB, we can collectively advance affordability of and global access to innovative biologics,” says Xueming Qian, PhD, chairman and CEO of Transcenta. “The proceeds from this and future collaborations will be reinvested to further strengthen our technology platform and advance our R&D pipeline to deliver next-generation, best in class therapeutics.” “This collaboration represents a win–win partnership that combines Transcenta’s innovation in continuous biomanufacturing and EirGenix’s proven bioprocessing and CDMO expertise,” adds Lee Cheng Liu, PhD, chairman and president of EirGenix. “Together, we aim to redefine how biologics are made—more efficiently, sustainably, and at lower cost—to reach more patients worldwide.” Transcenta has its headquarters and a discovery, clinical, and translational research center in Suzhou,…
